Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Phosphorylation of Sox2 at Threonine 116 is a Potential Marker to Identify a Subset of Breast Cancer Cells with High Tumorigenecity and Stem-Like Features.

Cancers (Basel). 2018; 
GuptaNidhi,GopalKeshav,WuChengsheng,AlshareefAbdulraheem,ChowAlexandra,WuFang,WangPeng,YeXiaoxia,BigrasGilbert,LaiRay
Products/Services Used Details Operation
Peptide Synthesis Mice which showed satisfactory immune response were selected for further hybridoma production step. mAB reactivity and antibody titer was determined by Genscript USA, Inc. by performing enzyme-linked immunosorbent assay (ELISA) with Sox2 and pSox2 peptide used as Cancers 2018, 10, 41 4 of 14 coating antigens. Get A Quote

摘要

We have previously identified a novel phenotypic dichotomy in breast cancer (BC) based on the response to a SRR2 (Sox2 regulatory region 2) reporter, with reporter responsive (RR) cells being more tumorigenic/stem-like than reporter unresponsive (RU) cells. Since the expression level of Sox2 is comparable between the two cell subsets, we hypothesized that post-translational modifications of Sox2 contribute to their differential reporter response and phenotypic differences. By liquid chromatography-mass spectrometry, we found Sox2 to be phosphorylated in RR but not RU cells. Threonine 116 is an important phosphorylation site, since transfection of the T116A mutant into RR cells significantly decreased th... More

关键词

Sox2,breast cancer,immunohistochemistry,intra-tumoral heterogeneity,phosphoryla
XML 地图